The significance of measurement of human placental lactogen, human chorionic gonadotropin, and carcinoembryonic antigen in patients with ovarian carcinoma.
Human placental lactogen (HPL or HCS), the beta subunit of human chorionic gonadotropin (beta-HCG), and carcinoembryonic antigen (CEA) were measured by a specific radioimmunoassay in plasma of 65 patients with ovarian cancer. Fifty-one patients had epithelial tumors, while 14 had germ cell tumors. It was found that 47 patients (72 per cent) had high levels of plasma HPL, 29 patients (45 per cent) had high levels of plasma beta-HCG, and 34 patients (52 per cent) had high levels of plasma CEA, but there was no correlation between these protein marker levels in different patients. Twenty of these patients were studied before and after operation and during chemotherapy and/or radiotherpy. There was no consistent correlation between these marker levels and the course of the disease. These data suggest that measurement of HPL, beta-HCG,  and CEA in sera of patients with ovarian cancer is not of value in assessing the clinical status of the patients or in determining the effect of therapy.
D000230:Adenocarcinoma / Q000097:blood; D002288:Adenocarcinoma, Mucinous / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002277:Carcinoma / Q000097:blood; D002822:Choriocarcinoma / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood*; D004407:Dysgerminoma / Q000097:blood; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000628:therapy; D010928:Placental Lactogen / Q000097:blood*; D011247:Pregnancy; D013724:Teratoma / Q000097:blood
D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D010928:Placental Lactogen